Monoclonal antibody (Mab) sB24M
Phase 1Biologic
Monoclonal antibody (Mab) sB24M is one of 10 biologic programs targeting Pyoderma. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Pyoderma
#DrugCompanyPhaseTrials
1Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Humira
CCelltrion
Phase 3
Velsipity
PfizerPhase 2
Taltz
Eli LillyPhase 2
Cosentyx
NovartisPhase 2
Ilaris
NovartisPhase 2
Spevigo
Boehringer IngelheimPhase 2
Hydroxymethylquinoxalindioxyde
VValenta Pharm JSC
Phase 3
Monoclonal antibody (Mab) sB24M
SSWISS BIOPHARMA MED GmbH
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- SSWISS BIOPHARMA MED GmbH